Stergios Moschos is an Oncology physician. OpenAlex indexes 26 publications with 1,098 citations (h-index 14); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5115 Centre Ave
Upmc Cancer Pavillion
Pittsburgh, PA 152321301
Telephone
412-623-2294Provider last certified this registry record 16 Dec 2020.
Clinical trials
- NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma
Sponsor: UNC Lineberger Comprehensive Cancer Center
- An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
Sponsor: UNC Lineberger Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20256 payments
- Partner Therapeutics, Inc.Program year20231 payment
- Seagen Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
33.3%Corticosteroid27%Prednisone100%Part D≥22 patientsH2 blocker6.3%Famotidine100%Part D<11 patientsSensory organs
19%Corticosteroid19%Hydrocortisone100%Part D<11 patientsNervous system
15.5%Opioid Agonist9.2%Oxycodone Hcl100%Part D<11 patientsOther antidepressants6.3%Mirtazapine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 914 The tumor microenvironment enforces ATF4 in CD8<sup>+</sup> TILs to obstruct immune checkpoint blockade efficacy
Regular and Young Investigator Award Abstracts
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”